Johnson & Johnson (J&J) is looking to emerging markets and diabetes care to propel future sales of devices and diagnostics, company executives said in a Jan. 24 earnings call. The call covered both fourth quarter and full year 2011 results. Diabetes products in the pipeline include blood glucose monitors, insulin pumps and artificial pancreas development, Chairman and CEO William Weldon said. Meanwhile, with countries like India, China, Russia and Brazil expected to account for 35 percent of healthcare spending growth through 2020, J&J is focused on developing products to meet emerging market needs, Weldon said.
Devices & Diagnostics Letter